UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.

Conclusion: UBE2C may be a novel therapy target for NSCLC for sensitizing cells to the chemotherapeutic agent DDP. PMID: 30693031 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research